Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 10, 2022

Effects of SGLT2is and Aldosterone Antagonists on Major Adverse Kidney Outcomes in Patients With T2D and CKD

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
Effects of sodium-glucose cotransporter 2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis
Diabetes Obes Metab 2022 Jun 16;[EPub Ahead of Print], S Yang, L Zhao, Y Mi, W He

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading